HC Wainwright & Co. reiterated coverage on Cardiff Oncology with a new price target

2/28/22 7:10:55 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

HC Wainwright & Co. reiterated coverage of Cardiff Oncology with a rating of Buy and set a new price target of $25.00 from $26.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRDF

Date	Price Target	Rating	Analyst
9/6/2024	$8.00	Buy	Craig Hallum
2/28/2022	$26.00 → $25.00	Buy	HC Wainwright & Co.
1/5/2022		Outperform	William Blair
12/8/2021	$19.00	Outperform	Robert W. Baird
12/8/2021	$19.00	Outperform	Baird
8/10/2021	$25.00 → $26.00	Buy	HC Wainwright & Co.
8/9/2021	$30.00 → $20.00	Buy	Maxim Group